Leadership, board oversight, and scientific collaborators

Dr. Marvin S. Hausman, MD

Chief Scientific Officer & Co-Founder · Xycota Biosciences

Contributed to the design of the behavioral and biochemical experiments in the 2026 Neuropsychopharmacology Fragile X rat study and leads Xycota’s translational strategy for XYCO-02 and preclinical exosome design for XYCO-01.

Immunologist and board-certified urological surgeon (NYU School of Medicine, 1967; Fellow of the American College of Surgeons) who served as a Surgeon in the U.S. Public Health Service (USPHS) at the National Institutes of Health (NIH, Bethesda, MD, 1969-1971), with more than 50 years in medicine and over 35 years in pharmaceutical and CNS drug development. Co-founder of Medco Research, Inc. (acquired by King Pharmaceuticals in 2000). Architect or developer of six FDA-approved NDAs, with senior R&D roles at Bristol-Myers Squibb and multiple biotechnology ventures. Previously served as Scientific Director at Nova Mentis Life Science Corp. at the time of the 2026 rat study design and the prior KGK Science low-dose Fragile X clinical program (Nova Mentis has since undergone corporate restructuring and ceased its research operations).

Brad Listermann

Co-Founder & CEO · Xycota Biosciences

Leads Xycota’s corporate strategy, intellectual property, capital formation, and clinical data and technology infrastructure, overseeing partner structuring, patent prosecution, and institutional governance across the XYCO-02 and XYCO-01 programs.

Co-Founder & CEO of PriviNet, where he architected Lumra (cryptographic HSM edge-proof and tamper-evident event verification) and Decern (a post-quantum cryptographic authorization and financial-safety airlock for autonomous AI agents). Named inventor on filed patent applications across AI, cybersecurity, and cryptographic verification, paired with over two decades of capital-markets and public-company leadership.

Lt. Col. Elton Johnson Jr. (Ret.)

Incoming Board Director / Advisor · Founder, AmeriVet Securities

Provides institutional financial governance, broker-dealer regulatory accountability, and veteran community oversight.

Founder & Non-Executive Chairman of AmeriVet Securities, Inc., a Service-Disabled Veteran-Owned FINRA-, SIPC-, and MSRB-registered institutional broker-dealer. Holds multi-decade regulatory governance credentials including FINRA Series 24 (General Securities Principal), Series 27 (Financial & Operations Principal / FINOP), Series 7, and Series 53 licenses, alongside a University of Notre Dame degree, graduate military education, and 37 years of U.S. Marine Corps and Army Reserve service (Iraq and Afghanistan; Bronze Star Medal).

Associate Professor Viviana Trezza, PhD

Associate Professor of Pharmacology · Roma Tre University (Italy)

Supervised the 2026 Neuropsychopharmacology Fragile X rat study and is its senior and corresponding author. Associate Professor of Pharmacology and Head of the Laboratory of Behavioral Pharmacology at Roma Tre University (study conducted in collaboration with the laboratory of Prof. Fabio Fumagalli at the University of Milan).

Dr. Louise Hecker, PhD

Scientific Collaborator · Baylor College of Medicine

Associate Professor of Medicine and regenerative biology investigator at Baylor College of Medicine (formerly Emory University School of Medicine). Senior author of the 2025 npj Aging publication examining psilocybin and psilocin in cultured human cells and aged mice.

Andrew Charrette, MSc

Director of Regulatory Affairs · KGK Science Inc. (Canada)

Guides preparation of Xycota’s planned Health Canada Clinical Trial Application (CTA) and Phase 1 PK/PD waiver request for XYCO-02. Director of Regulatory Affairs and Psychedelic Advisor at Canadian contract research organization KGK Science Inc. (MSc in Neuroscience, University of Ottawa; BSc in Pharmacology & Physiology, Western University), with experience across more than 100 North American clinical trial and regulatory submissions.